Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival among metastatic RMS patients has remained dismal yet unimproved for years. We previously identified the class I-specific histone deacetylase inhibitor, entinostat (ENT), as a pharm...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Skelet Muscle
Glavni autori: Bharathy, Narendra, Berlow, Noah E., Wang, Eric, Abraham, Jinu, Settelmeyer, Teagan P., Hooper, Jody E., Svalina, Matthew N., Bajwa, Zia, Goros, Martin W., Hernandez, Brian S., Wolff, Johannes E., Pal, Ranadip, Davies, Angela M., Ashok, Arya, Bushby, Darnell, Mancini, Maria, Noakes, Christopher, Goodwin, Neal C., Ordentlich, Peter, Keck, James, Hawkins, Douglas S., Rudzinski, Erin R., Mansoor, Atiya, Perkins, Theodore J., Vakoc, Christopher R., Michalek, Joel E., Keller, Charles
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6528217/
https://ncbi.nlm.nih.gov/pubmed/31113472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13395-019-0198-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items